The exact opposite of what you want
What Has Happened So Far Phase 1 (2019-2022) The Lancet in 2022, demonstrating that the triple agonist mechanism (GIP, GLP-1, and glucagon receptors) was tolerable in humans and showing promising early weight loss signals
Match it to the Certificate of Analysis on our COA page for HPLC purity data, MS identity confirmation, and production date giving researchers full traceability and reproducibility assurance for every experiment
However, the GLP-1 analog mimics the natural hormone in our body but does not degrade for days in the injection form creating a constant decreased desire to eat
doi:10.1136/bmj-2022-074068 Mller TD, Finan B, Bloom SR, et al
For more over-the-counter clinical guides and generic alternatives, visit our complete Digestive Health Hub